SCHEMBL680203

SCHEMBL680203

CC(C)c1ccccc1Oc1ccc(C(=O)NS(C)(=O)=O)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 1/20 0.45
BCL2L1 Q07817 2/20 0.43
MCL1 Q07820 2/20 0.43
HTR2A P28223 2/20 0.42
SLC6A4 P31645 2/20 0.42
HTT P42858 2/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
RAB9A P51151 1/20 0.41
PTPN1 P18031 1/20 0.41
LMNA P02545 1/20 0.40
SCN9A Q15858 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679939 0.82 MEN1 (0.60) SCN3ABCL2L1MCL1HTTKMT2A
SCHEMBL679956 0.82 MAPK14 (0.55) SCN3ABCL2L1MCL1HTTKMT2A
SCHEMBL680509 0.82 SCN3A (0.50) SCN3ABCL2L1MCL1KMT2AMEN1
SCHEMBL680159 0.81 CXCL8 (0.59) SCN3ABCL2L1MCL1PTPN1SCN9A
SCHEMBL680618 0.81 MAPK14 (0.54) SCN3AKMT2AMEN1LMNASCN9A
SCHEMBL2331776 0.80 BCL2 (0.52) MCL1HTR2ASLC6A4LMNAL3MBTL1
SCHEMBL680063 0.79 KDM4E (0.54) SCN3ABCL2L1MCL1HTTRAB9A
SCHEMBL680184 0.79 PTGS2 (0.53) SCN3ABCL2L1MCL1KMT2AMEN1
SCHEMBL680339 0.79 KMT2A (0.51) SCN3ABCL2L1MCL1HTTKMT2A
SCHEMBL679137 0.78 RORC (0.52) SCN3ABCL2L1MCL1SLC6A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010207-A1 Chemical Compounds SCN1A, SCN1B, SCN7A SCN3A 8/4885BCL2L1 3284/4885MCL1 2739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.